|
1
|
Xu W, Wang F, Ying L and Wang HH:
Association between glutathione S-transferase M1 null variant and
risk of bladder cancer in Chinese Han population. Tumour Biol.
35:773–777. 2014. View Article : Google Scholar
|
|
2
|
Costantini C and Millard F: Update on
chemotherapy in the treatment of urothelial carcinoma. Scientific
World Journal. 11:1981–1994. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shirato A, Kikugawa T, Miura N, Tanji N,
Takemori N, Higashiyama S and Yokoyama M: Cisplatin resistance by
induction of aldo-keto reductase family 1 member C2 in human
bladder cancer cells. Oncol Lett. 7:674–678. 2014.PubMed/NCBI
|
|
4
|
Galluzzi L, Vitale I, Michels J, Brenner
C, Szabadkai G, Harel-Bellan A, Castedo M and Kroemer G: Systems
biology of cisplatin resistance: Past, present and future. Cell
Death Dis. 5:e12572014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ding M, Fu X, Tan H, Wang R, Chen Z and
Ding S: The effect of vascular endothelial growth factor C
expression in tumor-associated macrophages on lymphangiogenesis and
lymphatic metastasis in breast cancer. Mol Med Rep. 6:1023–1029.
2012.PubMed/NCBI
|
|
6
|
Ciobanu M, Eremia IA, Crăiţoiu S,
Mărgăritescu CL, Stepan A, Pătraşcu V, Georgescu CC, Cernea D and
Dumitrescu D: Lymphatic microvessels density, VEGF-C and VEGFR-3
expression in 25 cases of breast invasive lobular carcinoma. Rom J
Morphol Embryol. 54:925–934. 2013.
|
|
7
|
Liu J, Cheng Y, He M and Yao S: Vascular
endothelial growth factor C enhances cervical cancer cell
invasiveness via upregulation of galectin-3 protein. Gynecol
Endocrinol. 30:461–465. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ma DM, Xu YP and Zhu L: Expression of
vascular endothelial growth factor C correlates with a poor
prognosis based on analysis of prognostic factors in patients with
cervical carcinomas. J Obstet Gynaecol Res. 37:1519–1524. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cho HJ, Kim IK, Park SM, et al: VEGF-C
mediates RhoGDI2-induced gastric cancer cell metastasis and
cisplatin resistance. Int J Cancer. 135:1553–1563. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Snoeren N, Emmink BL, Koerkamp MJ, et al:
Maspin is a marker for early recurrence in primary stage III and IV
colorectal cancer. Br J Cancer. 109:1636–1647. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Machowska M, Wachowicz K, Sopel M and
Rzepecki R: Nuclear location of tumor suppressor protein maspin
inhibits proliferation of breast cancer cells without affecting
proliferation of normal epithelial cells. BMC Cancer. 14:1422014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lopez-Ayllon BD, Moncho-Amor V, Abarrategi
A, Ibañez de Cáceres I, Castro-Carpeño J, Belda-Iniesta C, Perona R
and Sastre L: Cancer stem cells and cisplatin-resistant cells
isolated from non-small-lung cancer cell lines constitute related
cell populations. Cancer Med. 3:1099–1111. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhou BH, Huang JN, Zuo YL, Li BJ, Guo Q,
Cui BC, Shao WY, Du J and Bu XZ: 2a, a novel curcumin analog,
sensitizes cisplatin-resistant A549 cells to cisplatin by
inhibiting thioredoxin reductase concomitant oxidative stress
damage. Eur J Pharmacol. 707:130–139. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ajani JA, Wang X, Song S, et al: ALDH-1
expression levels predict response or resistance to preoperative
chemoradiation in resectable esophageal cancer patients. Mol Oncol.
8:142–149. 2014. View Article : Google Scholar :
|
|
15
|
Shen DW, Pouliot LM, Hall MD and Gottesman
MM: Cisplatin resistance: a cellular self-defense mechanism
resulting from multiple epigenetic and genetic changes. Pharmacol
Rev. 64:706–721. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jayachandran G, Ueda K, Wang B, Roth JA
and Ji L: NPRL2 sensitizes human non-small cell lung cancer (NSCLC)
cells to cisplatin treatment by regulating key components in the
DNA repair pathway. PLoS One. 5:e119942010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ling KS, Chen GD, Tsai HG, Lee MS, Wang PH
and Liu FS: Mechanisms involved in chemoresistance in ovarian
cancer. Taiwan J Obstet Gyne. 44:209–217. 2005. View Article : Google Scholar
|
|
18
|
Patel NP, Pattni BS, Abouzeid AH and
Torchilin VP: Nanopreparations to overcome multidrug resistance in
cancer. Adv Drug Deliver Rev. 65:1748–1762. 2013. View Article : Google Scholar
|
|
19
|
Hour TC, Lai YL, Kuan CI, et al:
Transcriptional up-regulation of SOD1 by CEBPD: a potential target
for cisplatin resistant human urothelial carcinoma cells. Biochem
Pharmacol. 80:325–334. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gutekunst M, Mueller T, Weilbacher A,
Dengler MA, Bedke J, Kruck S, Oren M, Aulitzky WE and van der Kuip
H: Cisplatin hypersensitivity of testicular germ cell tumors is
determined by high constitutive Noxa levels mediated by Oct-4.
Cancer Res. 73:1460–1469. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang J, Zhu Z, Sun Z, Sun X, Wang Z and
Xu H: Survivin gene expression increases gastric cancer cell
lymphatic metastasis by upregulating vascular endothelial growth
factor-C expression levels. Mol Med Rep. 9:600–606. 2014.
|
|
22
|
Li D, Xie K, Ding GT, Li J, Chen K, Li H,
Qian J, Jiang C and Fang J: Tumor resistance to anti-VEGF therapy
through up-regulation of VEGF-C expression. Cancer Lett. 346:45–52.
2014. View Article : Google Scholar
|
|
23
|
Hua KT, Lee WJ, Yang SF, Chen CK, Hsiao M,
Ku CC, Wei LH, Kuo ML and Chien MH: Vascular endothelial growth
factor-C modulates proliferation and chemoresistance in acute
myeloid leukemic cells through an endothelin-1-dependent induction
of cyclooxygenase-2. Biochim Biophys Acta. 1843:387–397. 2014.
View Article : Google Scholar
|
|
24
|
Stanton MJ, Dutta S, Zhang H, Polavaram
NS, Leontovich AA, Hönscheid P, Sinicrope FA, Tindall DJ, Muders MH
and Datta K: Autophagy control by the VEGF-C/NRP-2 axis in cancer
and its implication for treatment resistance. Cancer Res.
73:160–171. 2013. View Article : Google Scholar :
|
|
25
|
Zou Z, Anisowicz A, Hendrix MJ, Thor A,
Neveu M, Sheng S, Rafidi K, Seftor E and Sager R: Maspin, a serpin
with tumor-suppressing activity in human mammary epithelial cells.
Science. 263:526–529. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Taskiran C, Erdem O, Onan A, Vural C,
Arisoy O, Yildiz S and Guner H: Maspin expression in endometrial
hyperplasia and carcinoma and its relation with angiogenesis. Eur J
Gynaecol Oncol. 35:134–139. 2014.
|
|
27
|
Berardi R, Morgese F, Onofri A, et al:
Role of maspin in cancer. Clin Transl Med. 2:82013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hirai K, Koizumi K, Haraguchi S, et al:
Prognostic significance of the tumor suppressor gene maspin in
non-small cell lung cancer. Ann Thorac Surg. 79:248–253. 2005.
View Article : Google Scholar
|
|
29
|
Takanami I, Abiko T and Koizumi S:
Expression of maspin in non-small-cell lung cancer: Correlation
with clinical features. Clin Lung Cancer. 9:361–366. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Surowiak P, Materna V, Drag-Zalesinska M,
Wojnar A, Kaplenko I, Spaczyński M, Dietel M, Zabel M and Lage H:
Maspin expression is characteristic for cisplatin-sensitive ovarian
cancer cells and for ovarian cancer cases of longer survival rates.
Int J Gynecol Pathol. 25:131–139. 2006. View Article : Google Scholar : PubMed/NCBI
|
